Absci Corporation
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Absci Corporation (Nasdaq: ABSI) is a biotechnology company that develops generative AI models and integrated platforms for de novo design of novel proteins, antibodies, and biologics to accelerate drug discovery and development. The company offers its Integrated Drug Creation Platform, which combines generative AI, wet-lab automation, and data sciences; key components include the ABS platform for AI-driven protein design, de novo antibody generation services, and optimization of existing biologics for properties such as developability, stability, and affinity; as well as proprietary datasets and cloud-based software tools for protein engineering. Absci serves pharmaceutical and biotechnology companies targeting oncology, immunology, and metabolic diseases, with operations primarily in the United States and partnerships extending to global markets. Founded in 2011 and headquartered in Vancouver, Washington, the company recently expanded its capabilities through a strategic collaboration with Astellas Pharma in 2024 to co-develop de novo antibodies for an undisclosed target using Absci's generative AI platform; in early 2025, Absci announced a $200 million funding round led by new institutional investors to scale its AI infrastructure and advance multiple programs into preclinical stages; additionally, it launched an upgraded version of its ABS platform featuring enhanced multimodal AI models for faster iteration in therapeutic design.
Company News
Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
Critical Contrast: Absci (NASDAQ:ABSI) and Black Diamond Therapeutics (NASDAQ:BDTX)
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
Absci (NASDAQ:ABSI) vs. Silence Therapeutics (NASDAQ:SLN) Head to Head Contrast
Contrasting Absci (NASDAQ:ABSI) & Valneva (NASDAQ:VALN)
Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Absci: Positive Ph1 Data ABS-201 AGA And Several Catalysts Inbound (Upgrade)
Absci Corporation $ABSI Shares Bought by Bank of America Corp DE
Absci to Participate in Upcoming Investor Conferences
AMD's $1.3 Billion Portfolio Reveals Its Biggest Investments and Where AI Demand Lands Next
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
Absci Corporation (ABSI) Q2 2026 Earnings Call Transcript
Absci Q2 Earnings Call Highlights
Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)
Are Medical Stocks Lagging ABSCI CORP (ABSI) This Year?
A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed
Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should Know
Here's Why Absci Corporation (ABSI) is a Great Momentum Stock to Buy